1. Home
  2. AKRO

as 05-24-2024 4:00pm EST

$
-
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.

Founded: 2017 Country:
United States
United States
Employees: N/A City: SOUTH SAN FRANCISCO
Market Cap: 1.3B IPO Year: 2019
Target Price: $41.13 AVG Volume (30 days): 1.2M
Analyst Decision: Strong Buy Number of Analysts: 8
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -3.23 EPS Growth: N/A
52 Week Low/High: $11.25 - $58.38 Next Earning Date: 05-10-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

AKRO Daily Stock ML Predictions

Stock Insider Trading Activity of Akero Therapeutics Inc. (AKRO)

Name Ticker Relationship Date Transaction Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Young Jonathan AKRO Chief Operating Officer May 1 '24 Sell $20.15 5,000 $100,749.50 258,306 SEC Form 4
Yale Catriona AKRO Chief Development Officer Mar 13 '24 Sell $28.33 723 $20,482.59 77,692 SEC Form 4
Young Jonathan AKRO Chief Operating Officer Mar 13 '24 Sell $28.33 651 $18,442.83 268,306 SEC Form 4
White William Richard AKRO Chief Financial Officer Mar 13 '24 Sell $28.33 724 $20,510.92 49,630 SEC Form 4
Cheng Andrew AKRO President and CEO Mar 13 '24 Sell $28.33 1,969 $55,781.77 589,447 SEC Form 4
Cheng Andrew AKRO President and CEO Mar 4 '24 Sell $31.40 35,827 $1,124,974.97 630,589 SEC Form 4
Cheng Andrew AKRO President and CEO Mar 4 '24 Sell $32.28 6,770 $218,537.63 623,819 SEC Form 4
Cheng Andrew AKRO President and CEO Mar 4 '24 Sell $33.83 9,614 $325,266.62 614,205 SEC Form 4
Cheng Andrew AKRO President and CEO Mar 4 '24 Sell $34.63 14,680 $508,372.80 599,525 SEC Form 4
Cheng Andrew AKRO President and CEO Mar 4 '24 Sell $35.49 7,995 $283,775.33 591,530 SEC Form 4
Cheng Andrew AKRO President and CEO Mar 4 '24 Sell $36.28 114 $4,135.92 591,416 SEC Form 4
Yale Catriona AKRO Chief Development Officer Mar 4 '24 Sell $35.49 20,646 $732,726.54 78,415 SEC Form 4
Young Jonathan AKRO Chief Operating Officer Dec 27 '23 Sell $24.00 5,414 $129,936.00 185,131 SEC Form 4
Rolph Timothy AKRO Chief Scientific Officer Dec 14 '23 Sell $20.76 514 $10,670.64 182,672 SEC Form 4
Young Jonathan AKRO Chief Operating Officer Dec 14 '23 Sell $20.76 543 $11,272.68 185,131 SEC Form 4
Cheng Andrew AKRO President and CEO Dec 14 '23 Sell $20.76 1,628 $33,797.28 550,911 SEC Form 4
Graham G. Walmsley AKRO Director Dec 8 '23 Buy $19.85 50,000 $992,700.00 800,000 SEC Form 4
Graham G. Walmsley AKRO Director Dec 8 '23 Buy $19.80 50,000 $990,240.00 750,000 SEC Form 4
Graham G. Walmsley AKRO Director Nov 30 '23 Buy $16.90 50,000 $844,835.00 650,000 SEC Form 4
Graham G. Walmsley AKRO Director Nov 30 '23 Buy $16.99 50,000 $849,730.00 700,000 SEC Form 4
Young Jonathan AKRO Chief Operating Officer Nov 17 '23 Sell $14.68 30,000 $440,259.00 153,177 SEC Form 4

Share on Social Networks: